WWW.GENIAPHOTONICS.COM - Key Persons
François Gonthier, co-founders and CEO of Genia Photonics Inc., has over 25 years of experience in fiber optics industry. He received his B.Eng in Physics Engineering in 1985, his master and Ph. D in Optics in 1988 and 1993 respectively from École Polytechnique of Montreal. During his studies, he was the student with the greatest number of publications and was the first student to have patented and sold licenses to external companies that have successfully commercialized the products.
In 1997, he had co-founded ITF optical technologies that designed and manufactured fiber optics components for the telecommunications systems. He than occupied the position of CTO until 2006 when ITF was sold to Avensys. During this period ITF raised a total of 100 M$, and went from 3 to 500 employees in 2000-2001. In 2005, he led ITF to cash flow positive operation.
Dr. Gonthier had founded in 2006 FG2 Tech, a self-financed R&D; company that developed next generation fiber optics components for fiber lasers. FG2 Tech implemented a new process technology for fiber component fabrication resulting in a great reduction of cost. FG2 Tech's activities are today completely integrated in Genia Photonics'.
Dr. David Mercer has over 15 years of regulatory operations and leadership experience in the pharmaceutical industry. He is highly skilled in managing regulatory processes and has personally overseen over seventy initial applications, as well as hundreds of lifecycle sequences, across multiple global health authorities.
Dr. Emily Collins has over 18 years of dedicated experience in the pharmaceutical industry, specializing in regulatory operations and submissions. Her extensive expertise includes global submission management, technical requirements, and data standards crucial for pharmaceutical compliance. Throughout her career, Dr. Collins has led teams responsible for compiling, managing, and submitting thousands of investigational new drug (IND) applications and new drug applications (NDA) to regulatory authorities such as the FDA, Health Canada, and European Medicines Agency, supporting Centralised, Decentralised, and National procedure submissions.
Emily continuously refines her knowledge through hands-on experience, leveraging both her operational and regulatory expertise within the pharmaceutical sector. She remains at the forefront of emerging regulatory trends, actively participating in pilot programs and industry initiatives aimed at developing and documenting best practices and standards. Additionally, Dr. Collins frequently conducts high-impact, multidisciplinary training programs to help cross-functional pharmaceutical teams understand the requirements, nuances, and challenges of regulatory submissions.
Dr. Collins holds a Bachelor's degree in Biochemistry from Stanford University and a Ph.D. in Regulatory Science from the University of Southern California. Her unwavering commitment to regulatory excellence and her comprehensive understanding of the pharmaceutical regulatory landscape make her a valuable asset in advancing drug development and ensuring regulatory compliance.
Dr. Jonathan Meyers is a distinguished figure in the pharmaceutical services industry, bringing over 25 years of extensive expertise in regulatory affairs and clinical development. Throughout his career, Dr. Meyers has held a multitude of senior executive roles within both sponsor and service organizations. Prior to establishing PharmEX, Dr. Meyers was the Senior Vice President of Clinical Development at a leading biopharmaceutical company, where he successfully led the strategic development of early-stage drug candidates through Phase II clinical trials.
Before his tenure in clinical development, Dr. Meyers served as the Chief Operating Officer at a renowned therapeutics firm and Senior Vice President of Global Regulatory Affairs at a prominent pharma solutions provider. During this period, he oversaw comprehensive regulatory submissions and global clinical operations, significantly contributing to the growth and innovation within the companies. Dr. Meyers holds a Doctorate in Pharmacology from Harvard University and a Master of Science in Regulatory Science from Johns Hopkins University. His educational background and extensive professional experience make him a leader in the field, committed to advancing pharmaceutical development and ensuring regulatory compliance.